Cargando…
Therapeutic Delivery Specifications Identified Through Compartmental Analysis of a Mesenchymal Stromal Cell-Immune Reaction
Despite widespread preclinical success, mesenchymal stromal cell (MSC) therapy has not reached consistent pivotal clinical endpoints in primary indications of autoinflammatory diseases. Numerous studies aim to uncover specific mechanisms of action towards better control of therapy using in vitro imm...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5931547/ https://www.ncbi.nlm.nih.gov/pubmed/29717209 http://dx.doi.org/10.1038/s41598-018-24971-2 |
_version_ | 1783319657476784128 |
---|---|
author | Li, Matthew Khong, Danika Chin, Ling-Yee Singleton, Amy Parekkadan, Biju |
author_facet | Li, Matthew Khong, Danika Chin, Ling-Yee Singleton, Amy Parekkadan, Biju |
author_sort | Li, Matthew |
collection | PubMed |
description | Despite widespread preclinical success, mesenchymal stromal cell (MSC) therapy has not reached consistent pivotal clinical endpoints in primary indications of autoinflammatory diseases. Numerous studies aim to uncover specific mechanisms of action towards better control of therapy using in vitro immunomodulation assays. However, many of these immunomodulation assays are imperfectly designed to accurately recapitulate microenvironment conditions where MSCs act. To increase our understanding of MSC efficacy, we herein conduct a systems level microenvironment approach to define compartmental features that can influence the delivery of MSCs’ immunomodulatory effect in vitro in a more quantitative manner than ever before. Using this approach, we notably uncover an improved MSC quantification method with predictive cross-study applicability and unveil the key importance of system volume, time exposure to MSCs, and cross-communication between MSC and T cell populations to realize full therapeutic effect. The application of these compartmental analysis can improve our understanding of MSC mechanism(s) of action and further lead to administration methods that deliver MSCs within a compartment for predictable potency. |
format | Online Article Text |
id | pubmed-5931547 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-59315472018-08-29 Therapeutic Delivery Specifications Identified Through Compartmental Analysis of a Mesenchymal Stromal Cell-Immune Reaction Li, Matthew Khong, Danika Chin, Ling-Yee Singleton, Amy Parekkadan, Biju Sci Rep Article Despite widespread preclinical success, mesenchymal stromal cell (MSC) therapy has not reached consistent pivotal clinical endpoints in primary indications of autoinflammatory diseases. Numerous studies aim to uncover specific mechanisms of action towards better control of therapy using in vitro immunomodulation assays. However, many of these immunomodulation assays are imperfectly designed to accurately recapitulate microenvironment conditions where MSCs act. To increase our understanding of MSC efficacy, we herein conduct a systems level microenvironment approach to define compartmental features that can influence the delivery of MSCs’ immunomodulatory effect in vitro in a more quantitative manner than ever before. Using this approach, we notably uncover an improved MSC quantification method with predictive cross-study applicability and unveil the key importance of system volume, time exposure to MSCs, and cross-communication between MSC and T cell populations to realize full therapeutic effect. The application of these compartmental analysis can improve our understanding of MSC mechanism(s) of action and further lead to administration methods that deliver MSCs within a compartment for predictable potency. Nature Publishing Group UK 2018-05-01 /pmc/articles/PMC5931547/ /pubmed/29717209 http://dx.doi.org/10.1038/s41598-018-24971-2 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Li, Matthew Khong, Danika Chin, Ling-Yee Singleton, Amy Parekkadan, Biju Therapeutic Delivery Specifications Identified Through Compartmental Analysis of a Mesenchymal Stromal Cell-Immune Reaction |
title | Therapeutic Delivery Specifications Identified Through Compartmental Analysis of a Mesenchymal Stromal Cell-Immune Reaction |
title_full | Therapeutic Delivery Specifications Identified Through Compartmental Analysis of a Mesenchymal Stromal Cell-Immune Reaction |
title_fullStr | Therapeutic Delivery Specifications Identified Through Compartmental Analysis of a Mesenchymal Stromal Cell-Immune Reaction |
title_full_unstemmed | Therapeutic Delivery Specifications Identified Through Compartmental Analysis of a Mesenchymal Stromal Cell-Immune Reaction |
title_short | Therapeutic Delivery Specifications Identified Through Compartmental Analysis of a Mesenchymal Stromal Cell-Immune Reaction |
title_sort | therapeutic delivery specifications identified through compartmental analysis of a mesenchymal stromal cell-immune reaction |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5931547/ https://www.ncbi.nlm.nih.gov/pubmed/29717209 http://dx.doi.org/10.1038/s41598-018-24971-2 |
work_keys_str_mv | AT limatthew therapeuticdeliveryspecificationsidentifiedthroughcompartmentalanalysisofamesenchymalstromalcellimmunereaction AT khongdanika therapeuticdeliveryspecificationsidentifiedthroughcompartmentalanalysisofamesenchymalstromalcellimmunereaction AT chinlingyee therapeuticdeliveryspecificationsidentifiedthroughcompartmentalanalysisofamesenchymalstromalcellimmunereaction AT singletonamy therapeuticdeliveryspecificationsidentifiedthroughcompartmentalanalysisofamesenchymalstromalcellimmunereaction AT parekkadanbiju therapeuticdeliveryspecificationsidentifiedthroughcompartmentalanalysisofamesenchymalstromalcellimmunereaction |